TP53 and neoplasm: By selecting only tumours that harbour high-impact sequence variants (known pathogenic variants or most likely pathogenic variants assumed to have a disruptive impact on the protein) (Table 1) and matching them with the IHC-staining of p53, it was observed that the majority of sequence variants were found in weak or strong p53-staining IDCs (Figure 2).